Table 2 displays clinical features. The FLVCR2 level significantly elevated in AML bone marrow in comparison with that of controls (p < 0.01, Figure 7A). The expression of FLVCR2 depended on the efficacy of the therapy. The FLVCR2 levels were significantly reduced during therapy when patients achieved complete remission but remained constant in those with no remission. FLVCR2 expression was higher in relapsed or refractory AML cases (n = 15, p < 0.01) than in those achieving complete response (n = 15, Figure 7B). The gene discussed is FLVCR2; the disease is acute myeloid leukemia.